Understanding how RUNX1 contributes to skin fibrosis in systemic sclerosis.
Deciphering the Mechanism of RUNX1 in Systemic Sclerosis (SSc) Dermal Fibrosis
['FUNDING_FELLOWSHIP'] · DARTMOUTH COLLEGE · NIH-11070677
This study is looking at how a protein called RUNX1 affects skin thickening in people with systemic sclerosis, a condition that causes hardening of the skin, to help find new ways to treat it and improve patients' lives.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DARTMOUTH COLLEGE (nih funded) |
| Locations | 1 site (HANOVER, UNITED STATES) |
| Trial ID | NIH-11070677 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the RUNX1 protein in the development of skin fibrosis associated with systemic sclerosis (SSc), an autoimmune disease. By analyzing gene expression and utilizing advanced techniques like single-cell RNA sequencing and a 3D tissue model, the study aims to uncover how RUNX1 influences the transition of skin cells into fibrotic cells. The goal is to better understand the mechanisms behind SSc and identify potential therapeutic targets for improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with diffuse cutaneous systemic sclerosis who are experiencing skin fibrosis.
Not a fit: Patients with other forms of autoimmune diseases that do not involve skin fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce skin fibrosis and improve the quality of life for patients with systemic sclerosis.
How similar studies have performed: Previous research has shown promising results in understanding the role of RUNX1 in other fibrotic conditions, suggesting that this approach may yield valuable insights.
Where this research is happening
HANOVER, UNITED STATES
- DARTMOUTH COLLEGE — HANOVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARVIZI, REZVAN — DARTMOUTH COLLEGE
- Study coordinator: PARVIZI, REZVAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder